Vor Biopharma Inc.

VOR

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
SEC CIK: 0001817229

SEC filings (opens in a new tab)

In the last 90 days, Vor Biopharma Inc. insiders filed 0 open-market purchases and 1 sale; 102 institutions reported holding it in 13F filings for Q2 2026, worth $893.0M in total; no superinvestor holds it.

Q4 2022 vs. Q3 2022

How the institutions holding Vor Biopharma Inc. changed between Q3 2022 and Q4 2022.

All holders in Q4 2022 All holders in Q3 2022

13F holders of VOR: Q3 2022 compared with Q4 2022
Measure	Q3 2022	Q4 2022	Change
Holders	48	58	+10
Shares	31.5M	60.2M	+28.7M (+90.9%)
Value	$125.5M	$400.3M	+$274.8M (+218.9%)

New holders (15)

Institutions that held Vor Biopharma Inc. at the end of Q4 2022 but not at the end of Q3 2022.

Institutions new to VOR in Q4 2022
Institution	Shares	Value	% of portfolio
Janus Henderson Group PLC	1,860,465	$12.4M	0.01%
Walleye Capital LLC	163,388	$1.09M	0.02%
AWM Investment Company, Inc.	100,000	$665.0K	0.10%
Trustees of Columbia University in the City of New York	91,910	$611.0K	1.26%
D. E. Shaw & Co., Inc.	50,901	$338.5K	0.00%
Susquehanna International Group, LLP	47,897	$318.5K	0.00%
Marshall Wace, LLP	30,487	$202.7K	0.00%
683 Capital Management, LLC	25,419	$169.0K	0.02%
HRT Financial LP	17,924	$119.0K	0.00%
Man Group plc	16,953	$112.7K	0.00%
Boothbay Fund Management, LLC	14,320	$95.2K	0.00%
Bank of New York Mellon Corp	12,245	$81.4K	0.00%
Grimes & Company, Inc.	10,856	$72.2K	0.00%
UBS Group AG	4,087	$27.2K	0.00%
Lazard Asset Management LLC	1,614	$10.0K	0.00%

Sold out (5)

Institutions that held Vor Biopharma Inc. at the end of Q3 2022 and filed for Q4 2022 without it.

Institutions that sold out of VOR in Q4 2022
Institution	Shares, Q3 2022	Value, Q3 2022
Ally Bridge Group (NY) LLC	255,162	$1.02M
OrbiMed Advisors LLC	111,808	$445.0K
Goldman Sachs Group Inc	19,062	$76.0K
China Universal Asset Management Co., Ltd.	356	$1.00K
Daiwa Securities Group Inc.	109	$0